Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics to Present at CARB-X Investor Day
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell?
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell?
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
More companies adopt co-CEO structure
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
Seres (MCRB) Q2 Loss Narrows 34%
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript